Healthcare provider profile · identity verified

Casey S Prough, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · LEES SUMMIT, MO · NPI 1396723706

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Casey S Prough, MD received $109,228.67 in general payments during 2025 across 286 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 50.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 23 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Caplyta, Ingrezza, Rexulti, Spravato, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Vraylar by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Spravato by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo Xr by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$109,228.67

286 reported records · 20 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$55,340.15	50.7%	97	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$38,113.91	34.9%	69	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$9,328.17	8.5%	20	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$4,434.58	4.1%	12	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$332.12	0.3%	16	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$298.64	0.3%	12	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$285.60	0.3%	10	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$243.13	0.2%	9	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$220.89	0.2%	12	2025
Corium, LLC	Unresolved — no canonical attribution shown	$131.61	0.1%	5	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$111.32	0.1%	5	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$95.92	0.1%	4	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$89.73	0.1%	5	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$81.25	0.1%	4	2025
HARMONY BIOSCIENCES LLC	Unresolved — no canonical attribution shown	$28.81	0.0%	1	2025
Otsuka Pharmaceutical Development & Commercialization, Inc.	Unresolved — no canonical attribution shown	$26.87	0.0%	1	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$17.89	0.0%	1	2025
Noven Therapeutics, LLC	Unresolved — no canonical attribution shown	$17.31	0.0%	1	2025
Tonix Medicines, Inc.	Unresolved — no canonical attribution shown	$16.97	0.0%	1	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$13.80	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$97,525.00	43
Food and Beverage	$4,755.11	201
Consulting Fee	$3,520.00	1
Travel and Lodging	$3,428.56	41

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$55,340.15	97	2025
Source payment records 2025-01-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.88 · Open Payments source 2025-01-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.58 · Open Payments source 2025-01-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.95 · Open Payments source 2025-01-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-01-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.00 · Open Payments source 2025-02-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.92 · Open Payments source 2025-02-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.72 · Open Payments source 2025-02-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.86 · Open Payments source 2025-02-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-02-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.40 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.50 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.27 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.40 · Open Payments source 2025-03-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.86 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.79 · Open Payments source 2025-04-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.73 · Open Payments source 2025-04-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.02 · Open Payments source 2025-04-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.50 · Open Payments source 2025-05-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $67.20 · Open Payments source 2025-05-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-05-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.67 · Open Payments source 2025-05-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.90 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.75 · Open Payments source 2025-06-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.17 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.53 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $42.00 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-07-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-07-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.15 · Open Payments source 2025-07-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-07-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.40 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.56 · Open Payments source 2025-08-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.46 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.02 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.87 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.40 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.52 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $37.80 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $95.90 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $54.60 · Open Payments source 2025-09-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.25 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.63 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.82 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $166.60 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,320.00 · Open Payments source 2025-10-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.12 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.08 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $443.96 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $235.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.19 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.07 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.52 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.08 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $185.00 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.83 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $42.27 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.80 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.80 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.71 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $41.58 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $35.00 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.84 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.43 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.04 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.99 · Open Payments source 2025-11-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.37 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $95.90 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $98.70 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $51.80 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.06 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.49 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.40 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $37.80 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$38,113.91	69	2025
Source payment records 2025-01-14 · ABBVIE INC. · $17.17 · Open Payments source 2025-01-29 · ABBVIE INC. · $2.28 · Open Payments source 2025-01-30 · ABBVIE INC. · $20.73 · Open Payments source 2025-02-27 · ABBVIE INC. · $24.37 · Open Payments source 2025-02-28 · ABBVIE INC. · $126.00 · Open Payments source 2025-02-28 · ABBVIE INC. · $10.04 · Open Payments source 2025-03-21 · ABBVIE INC. · $28.21 · Open Payments source 2025-03-25 · ABBVIE INC. · $3,150.00 · Open Payments source 2025-03-26 · ABBVIE INC. · $21.85 · Open Payments source 2025-03-26 · ABBVIE INC. · $29.40 · Open Payments source 2025-04-07 · ABBVIE INC. · $1.94 · Open Payments source 2025-04-08 · ABBVIE INC. · $20.18 · Open Payments source 2025-04-18 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-04-22 · ABBVIE INC. · $22.70 · Open Payments source 2025-04-22 · ABBVIE INC. · $26.60 · Open Payments source 2025-04-22 · ABBVIE INC. · $21.77 · Open Payments source 2025-04-25 · ABBVIE INC. · $23.12 · Open Payments source 2025-04-25 · ABBVIE INC. · $35.00 · Open Payments source 2025-04-30 · ABBVIE INC. · $30.14 · Open Payments source 2025-04-30 · ABBVIE INC. · $35.00 · Open Payments source 2025-05-02 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-05-12 · ABBVIE INC. · $29.40 · Open Payments source 2025-05-12 · ABBVIE INC. · $12.54 · Open Payments source 2025-05-14 · ABBVIE INC. · $15.91 · Open Payments source 2025-05-14 · ABBVIE INC. · $79.80 · Open Payments source 2025-05-16 · ABBVIE INC. · $29.14 · Open Payments source 2025-05-16 · ABBVIE INC. · $7.00 · Open Payments source 2025-05-16 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-05-16 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-06-03 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-06-03 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-06-04 · ABBVIE INC. · $37.80 · Open Payments source 2025-06-04 · ABBVIE INC. · $0.02 · Open Payments source 2025-06-10 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-06-16 · ABBVIE INC. · $20.79 · Open Payments source 2025-06-16 · ABBVIE INC. · $195.30 · Open Payments source 2025-06-16 · ABBVIE INC. · $161.75 · Open Payments source 2025-06-16 · ABBVIE INC. · $8.07 · Open Payments source 2025-06-16 · ABBVIE INC. · $196.00 · Open Payments source 2025-06-17 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-06-30 · ABBVIE INC. · $15.97 · Open Payments source 2025-07-02 · ABBVIE INC. · $3,150.00 · Open Payments source 2025-07-02 · ABBVIE INC. · $3,150.00 · Open Payments source 2025-07-08 · ABBVIE INC. · $21.90 · Open Payments source 2025-07-16 · ABBVIE INC. · $2.70 · Open Payments source 2025-07-16 · ABBVIE INC. · $1.35 · Open Payments source 2025-07-17 · ABBVIE INC. · $17.57 · Open Payments source 2025-07-29 · ABBVIE INC. · $2.32 · Open Payments source 2025-07-30 · ABBVIE INC. · $23.99 · Open Payments source 2025-08-11 · ABBVIE INC. · $32.35 · Open Payments source 2025-08-20 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-08-20 · ABBVIE INC. · $29.19 · Open Payments source 2025-08-28 · ABBVIE INC. · $21.59 · Open Payments source 2025-09-15 · ABBVIE INC. · $31.73 · Open Payments source 2025-09-16 · ABBVIE INC. · $10.38 · Open Payments source 2025-09-16 · ABBVIE INC. · $3.33 · Open Payments source 2025-09-18 · ABBVIE INC. · $20.85 · Open Payments source 2025-10-02 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-10-09 · ABBVIE INC. · $29.21 · Open Payments source 2025-10-09 · ABBVIE INC. · $30.80 · Open Payments source 2025-10-13 · ABBVIE INC. · $2.18 · Open Payments source 2025-10-14 · ABBVIE INC. · $20.38 · Open Payments source 2025-10-23 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-10-28 · ABBVIE INC. · $9.38 · Open Payments source 2025-10-28 · ABBVIE INC. · $3.31 · Open Payments source 2025-11-07 · ABBVIE INC. · $21.99 · Open Payments source 2025-11-19 · ABBVIE INC. · $1.51 · Open Payments source 2025-11-20 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-11-20 · ABBVIE INC. · $19.91 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$9,439.49	25	2025
Source payment records 2025-01-23 · Otsuka America Pharmaceutical, Inc. · $20.34 · Open Payments source 2025-02-25 · Otsuka America Pharmaceutical, Inc. · $11.74 · Open Payments source 2025-03-26 · Lundbeck LLC · $26.45 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $13.82 · Open Payments source 2025-04-14 · Lundbeck LLC · $25.96 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source 2025-05-08 · Otsuka America Pharmaceutical, Inc. · $20.80 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-16 · Otsuka America Pharmaceutical, Inc. · $9.80 · Open Payments source 2025-05-22 · Otsuka America Pharmaceutical, Inc. · $17.08 · Open Payments source 2025-05-28 · Lundbeck LLC · $20.60 · Open Payments source 2025-05-29 · Otsuka America Pharmaceutical, Inc. · $116.65 · Open Payments source 2025-06-04 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source 2025-06-18 · Otsuka America Pharmaceutical, Inc. · $37.80 · Open Payments source 2025-06-25 · Lundbeck LLC · $13.57 · Open Payments source 2025-07-22 · Otsuka America Pharmaceutical, Inc. · $21.93 · Open Payments source 2025-08-13 · Otsuka America Pharmaceutical, Inc. · $34.44 · Open Payments source 2025-09-17 · Lundbeck LLC · $24.74 · Open Payments source 2025-10-17 · Otsuka America Pharmaceutical, Inc. · $26.75 · Open Payments source 2025-10-22 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source 2025-11-11 · Otsuka America Pharmaceutical, Inc. · $19.73 · Open Payments source 2025-11-11 · Otsuka America Pharmaceutical, Inc. · $97.29 · Open Payments source 2025-11-14 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source 2025-11-28 · Otsuka America Pharmaceutical, Inc. · $70.00 · Open Payments source 2025-11-28 · Otsuka America Pharmaceutical, Inc. · $35.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$4,434.58	12	2025
Source payment records 2025-02-04 · E.R. Squibb & Sons, L.L.C. · $12.72 · Open Payments source 2025-04-16 · E.R. Squibb & Sons, L.L.C. · $14.54 · Open Payments source 2025-05-20 · E.R. Squibb & Sons, L.L.C. · $23.88 · Open Payments source 2025-06-18 · E.R. Squibb & Sons, L.L.C. · $24.15 · Open Payments source 2025-07-02 · E.R. Squibb & Sons, L.L.C. · $7.33 · Open Payments source 2025-07-25 · E.R. Squibb & Sons, L.L.C. · $1,840.00 · Open Payments source 2025-08-28 · E.R. Squibb & Sons, L.L.C. · $123.60 · Open Payments source 2025-09-15 · E.R. Squibb & Sons, L.L.C. · $2,300.00 · Open Payments source 2025-09-24 · E.R. Squibb & Sons, L.L.C. · $16.54 · Open Payments source 2025-09-29 · E.R. Squibb & Sons, L.L.C. · $42.00 · Open Payments source 2025-10-15 · E.R. Squibb & Sons, L.L.C. · $12.04 · Open Payments source 2025-12-10 · E.R. Squibb & Sons, L.L.C. · $17.78 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$332.12	16	2025
Source payment records 2025-01-09 · Neurocrine BioSciences, Inc. · $21.22 · Open Payments source 2025-01-17 · Neurocrine BioSciences, Inc. · $29.92 · Open Payments source 2025-01-22 · Neurocrine BioSciences, Inc. · $13.84 · Open Payments source 2025-01-30 · Neurocrine BioSciences, Inc. · $3.61 · Open Payments source 2025-01-31 · Neurocrine BioSciences, Inc. · $30.37 · Open Payments source 2025-02-20 · Neurocrine BioSciences, Inc. · $30.55 · Open Payments source 2025-02-25 · Neurocrine BioSciences, Inc. · $12.79 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $26.42 · Open Payments source 2025-04-01 · Neurocrine BioSciences, Inc. · $15.87 · Open Payments source 2025-05-07 · Neurocrine BioSciences, Inc. · $25.14 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $4.00 · Open Payments source 2025-05-16 · Neurocrine BioSciences, Inc. · $35.85 · Open Payments source 2025-05-21 · Neurocrine BioSciences, Inc. · $22.34 · Open Payments source 2025-10-02 · Neurocrine BioSciences, Inc. · $16.03 · Open Payments source 2025-11-06 · Neurocrine BioSciences, Inc. · $25.17 · Open Payments source 2025-11-26 · Neurocrine BioSciences, Inc. · $19.00 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$285.60	10	2025
Source payment records 2025-02-06 · Vanda Pharmaceuticals Inc. · $42.01 · Open Payments source 2025-03-06 · Vanda Pharmaceuticals Inc. · $32.39 · Open Payments source 2025-04-08 · Vanda Pharmaceuticals Inc. · $18.44 · Open Payments source 2025-05-08 · Vanda Pharmaceuticals Inc. · $36.27 · Open Payments source 2025-06-05 · Vanda Pharmaceuticals Inc. · $37.21 · Open Payments source 2025-08-06 · Vanda Pharmaceuticals Inc. · $19.96 · Open Payments source 2025-09-25 · Vanda Pharmaceuticals Inc. · $31.52 · Open Payments source 2025-11-20 · Vanda Pharmaceuticals Inc. · $34.25 · Open Payments source 2025-12-15 · Vanda Pharmaceuticals Inc. · $8.29 · Open Payments source 2025-12-16 · Vanda Pharmaceuticals Inc. · $25.26 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$243.13	9	2025
Source payment records 2025-01-16 · Alkermes, Inc. · $25.88 · Open Payments source 2025-03-31 · Alkermes, Inc. · $27.14 · Open Payments source 2025-04-17 · Alkermes, Inc. · $23.10 · Open Payments source 2025-06-09 · Alkermes, Inc. · $27.93 · Open Payments source 2025-07-17 · Alkermes, Inc. · $32.04 · Open Payments source 2025-08-04 · Alkermes, Inc. · $23.50 · Open Payments source 2025-09-29 · Alkermes, Inc. · $28.32 · Open Payments source 2025-10-20 · Alkermes, Inc. · $33.61 · Open Payments source 2025-11-03 · Alkermes, Inc. · $21.61 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$224.54	8	2025
Source payment records 2025-01-02 · Janssen Pharmaceuticals, Inc · $13.26 · Open Payments source 2025-01-23 · Janssen Pharmaceuticals, Inc · $7.10 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $12.86 · Open Payments source 2025-03-19 · Janssen Pharmaceuticals, Inc · $17.71 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $11.60 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $15.70 · Open Payments source 2025-09-30 · Janssen Pharmaceuticals, Inc · $142.68 · Open Payments source 2025-10-14 · Janssen Pharmaceuticals, Inc · $3.63 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$215.99	8	2025
Source payment records 2025-01-16 · Alkermes, Inc. · $25.88 · Open Payments source 2025-04-17 · Alkermes, Inc. · $23.10 · Open Payments source 2025-06-09 · Alkermes, Inc. · $27.93 · Open Payments source 2025-07-17 · Alkermes, Inc. · $32.04 · Open Payments source 2025-08-04 · Alkermes, Inc. · $23.50 · Open Payments source 2025-09-29 · Alkermes, Inc. · $28.32 · Open Payments source 2025-10-20 · Alkermes, Inc. · $33.61 · Open Payments source 2025-11-03 · Alkermes, Inc. · $21.61 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$131.61	5	2025
Source payment records 2025-06-17 · Corium, LLC · $27.46 · Open Payments source 2025-08-07 · Corium, LLC · $23.00 · Open Payments source 2025-09-11 · Corium, LLC · $31.63 · Open Payments source 2025-10-29 · Corium, LLC · $24.44 · Open Payments source 2025-12-17 · Corium, LLC · $25.08 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$121.65	5	2025
Source payment records 2025-01-14 · Teva Pharmaceuticals USA, Inc. · $28.42 · Open Payments source 2025-04-24 · Teva Pharmaceuticals USA, Inc. · $24.18 · Open Payments source 2025-05-29 · Teva Pharmaceuticals USA, Inc. · $18.33 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $32.79 · Open Payments source 2025-10-08 · Teva Pharmaceuticals USA, Inc. · $17.93 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$99.24	7	2025
Source payment records 2025-01-21 · Teva Pharmaceuticals USA, Inc. · $18.35 · Open Payments source 2025-02-05 · Teva Pharmaceuticals USA, Inc. · $17.16 · Open Payments source 2025-04-01 · Teva Pharmaceuticals USA, Inc. · $18.53 · Open Payments source 2025-05-05 · Teva Pharmaceuticals USA, Inc. · $15.19 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $7.22 · Open Payments source 2025-09-25 · Teva Pharmaceuticals USA, Inc. · $15.46 · Open Payments source 2025-11-24 · Teva Pharmaceuticals USA, Inc. · $7.33 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$95.92	4	2025
Source payment records 2025-05-05 · Bausch Health US, LLC · $24.99 · Open Payments source 2025-07-09 · Bausch Health US, LLC · $24.48 · Open Payments source 2025-07-23 · Bausch Health US, LLC · $24.17 · Open Payments source 2025-10-22 · Bausch Health US, LLC · $22.28 · Open Payments source
HETLIOZ Normalized: hetlioz	Drug	Vanda Pharmaceuticals Inc.	$92.84	3	2025
Source payment records 2025-02-06 · Vanda Pharmaceuticals Inc. · $42.01 · Open Payments source 2025-03-06 · Vanda Pharmaceuticals Inc. · $32.39 · Open Payments source 2025-04-08 · Vanda Pharmaceuticals Inc. · $18.44 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$89.73	5	2025
Source payment records 2025-01-15 · Axsome Therapeutics, Inc. · $14.81 · Open Payments source 2025-02-20 · Axsome Therapeutics, Inc. · $14.14 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $26.46 · Open Payments source 2025-11-12 · Axsome Therapeutics, Inc. · $19.51 · Open Payments source 2025-12-11 · Axsome Therapeutics, Inc. · $14.81 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$81.25	4	2025
Source payment records 2025-02-19 · Supernus Pharmaceuticals, Inc. · $17.11 · Open Payments source 2025-03-12 · Supernus Pharmaceuticals, Inc. · $18.69 · Open Payments source 2025-04-10 · Supernus Pharmaceuticals, Inc. · $22.42 · Open Payments source 2025-05-15 · Supernus Pharmaceuticals, Inc. · $23.03 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$74.10	4	2025
Source payment records 2025-01-28 · Janssen Pharmaceuticals, Inc · $10.72 · Open Payments source 2025-02-19 · Janssen Pharmaceuticals, Inc · $19.71 · Open Payments source 2025-04-22 · Janssen Pharmaceuticals, Inc · $18.74 · Open Payments source 2025-08-19 · Janssen Pharmaceuticals, Inc · $24.93 · Open Payments source
WAKIX Normalized: wakix	Drug	HARMONY BIOSCIENCES LLC	$28.81	1	2025
Source payment records 2025-10-06 · HARMONY BIOSCIENCES LLC · $28.81 · Open Payments source
REJOYN Normalized: rejoyn	Device	Otsuka Pharmaceutical Development & Commercialization, Inc.	$26.87	1	2025
Source payment records 2025-11-04 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $26.87 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$17.89	1	2025
Source payment records 2025-01-08 · Tris Pharma Inc · $17.89 · Open Payments source
Xelstrym Normalized: xelstrym	Drug	Noven Therapeutics, LLC	$17.31	1	2025
Source payment records 2025-04-09 · Noven Therapeutics, LLC · $17.31 · Open Payments source
TONMYA Normalized: tonmya	Drug	Tonix Medicines, Inc.	$16.97	1	2025
Source payment records 2025-11-20 · Tonix Medicines, Inc. · $16.97 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$13.80	1	2025
Source payment records 2025-04-09 · Collegium Pharmaceutical, Inc. · $13.80 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
AUSTEDO XR austedo xr	2025	Austedo Xr	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	81 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	25 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	20 Beneficiary count suppressed	exact normalized	Medicare Part D
SPRAVATO spravato	2025	Spravato	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	50 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	50	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	81	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	81	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	SPRAVATO open payments reported associated product	CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254	Spravato · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	25	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865	Rexulti · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO XR open payments reported associated product	CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228	Austedo Xr · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Alprazolam	Alprazolam	560	75
Trazodone Hcl	Trazodone Hcl	391	83
Clonazepam	Clonazepam	316	47
Bupropion Xl	Bupropion Hcl	264	43
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	253	33
Duloxetine Hcl	Duloxetine Hcl	228	46
Escitalopram Oxalate	Escitalopram Oxalate	222	45
Lamotrigine	Lamotrigine	192	37
Sertraline Hcl	Sertraline Hcl	192	31
Quetiapine Fumarate	Quetiapine Fumarate	185	29
Oxcarbazepine	Oxcarbazepine	184	28
Gabapentin	Gabapentin	168	31
Risperidone	Risperidone	167	19
Buspirone Hcl	Buspirone Hcl	161	29
Aripiprazole	Aripiprazole	149	31
Lorazepam	Lorazepam	126	20
Fluoxetine Hcl	Fluoxetine Hcl	117	18
Hydroxyzine Hcl	Hydroxyzine Hcl	97	19
Diazepam	Diazepam	89	15
Methylphenidate Hcl	Methylphenidate Hcl	88	13
Olanzapine	Olanzapine	86	12
Caplyta	Lumateperone Tosylate	81	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	78	19
Loxapine	Loxapine Succinate	75	suppressed
Doxepin Hcl	Doxepin Hcl	74	12
Mirtazapine	Mirtazapine	72	17
Ziprasidone Hcl	Ziprasidone Hcl	72	suppressed
Citalopram Hbr	Citalopram Hydrobromide	71	11
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	69	11
Prazosin Hcl	Prazosin Hcl	68	11
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	63	suppressed
Propranolol Hcl	Propranolol Hcl	63	12
Venlafaxine Hcl Er	Venlafaxine Hcl	61	12
Bupropion Hcl Sr	Bupropion Hcl	58	suppressed
Lithium Carbonate Er	Lithium Carbonate	56	suppressed
Haloperidol	Haloperidol	52	suppressed
Vraylar	Cariprazine Hcl	50	suppressed
Benztropine Mesylate	Benztropine Mesylate	47	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	47	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	46	12
Topiramate	Topiramate	46	suppressed
Donepezil Hcl	Donepezil Hcl	44	suppressed
Lurasidone Hcl	Lurasidone Hcl	42	11
Divalproex Sodium Er	Divalproex Sodium	36	suppressed
Eszopiclone	Eszopiclone	35	suppressed
Lithium Carbonate	Lithium Carbonate	31	suppressed
Methylphenidate Er	Methylphenidate Hcl	27	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	26	suppressed
Ingrezza	Valbenazine Tosylate	25	suppressed
Clozaril	Clozapine	24	suppressed
Trintellix	Vortioxetine Hydrobromide	24	suppressed
Carbamazepine	Carbamazepine	23	suppressed
Olanzapine Odt	Olanzapine	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	21	suppressed
Rexulti	Brexpiprazole	20	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	20	suppressed
Guanfacine Hcl	Guanfacine Hcl	18	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	17	suppressed
Belsomra	Suvorexant	16	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	14	suppressed
Dextroamphetamine Sulfate Er	Dextroamphetamine Sulfate	14	suppressed
Fetzima	Levomilnacipran Hcl	14	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	13	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	13	suppressed
Armodafinil	Armodafinil	12	suppressed
Austedo Xr	Deutetrabenazine	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Famotidine	Famotidine	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Spravato	Esketamine Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed
Zaleplon	Zaleplon	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$109,228.67 · 286 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, REJOYN, REXULTI, SPRAVATO, TONMYA, UZEDY, VRAYLAR, WAKIX, Xelstrym	9	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Austedo Xr play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error